PCM
BIO icon

Portolan Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Portolan Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.95M Sell
14,173
-19,986
-59% -$5.76M 0.21% 111
2025
Q4 		$10.3M Sell
34,159
-12,281
-26% -$3.83M 0.55% 62
2025
Q3 		$13M Sell
46,440
-16,344
-26% -$4.45M 0.7% 47
2025
Q2 		$15.2M Buy
62,784
+41,044
+189% +$9.7M 0.95% 36
2025
Q1 		$5.29M Sell
21,740
-8,846
-29% -$2.66M 0.4% 70
2024
Q4 		$10M Buy
30,586
+8,686
+40% +$2.95M 0.68% 51
2024
Q3 		$7.33M Sell
21,900
-3,250
-13% -$1.03M 0.53% 65
2024
Q2 		$6.87M Sell
25,150
-65,842
-72% -$19.2M 0.57% 64
2024
Q1 		$31.5M Buy
90,992
+33,718
+59% +$11.1M 2.4% 5
2023
Q4 		$18.5M Buy
57,274
+14,788
+35% +$4.64M 1.62% 14
2023
Q3 		$15.2M Sell
42,486
-22,553
-35% -$8.7M 1.42% 21
2023
Q2 		$24.7M Buy
65,039
+10,679
+20% +$4.35M 2.18% 10
2023
Q1 		$26M Sell
54,360
-7,693
-12% -$3.6M 2.48% 5
2022
Q4 		$26.1M Buy
62,053
+17,126
+38% +$6.91M 2.59% 3
2022
Q3 		$18.7M Buy
44,927
+2,965
+7% +$1.48M 1.98% 11
2022
Q2 		$20.8M Buy
41,962
+7,659
+22% +$3.99M 2.09% 8
2022
Q1 		$19.3M Buy
34,303
+14,582
+74% +$8.79M 1.54% 17
2021
Q4 		$14.9M Sell
19,721
-5,222
-21% -$3.91M 1% 41
2021
Q3 		$18.6M Buy
24,943
+13,394
+116% +$10M 1.36% 28
2021
Q2 		$7.44M Sell
11,549
-539
-4% -$328K 0.54% 72
2021
Q1 		$6.9M Sell
12,088
-31
-0.3% -$18.4K 0.54% 78
2020
Q4 		$7.07M Sell
12,119
-5,738
-32% -$3.27M 0.64% 60
2020
Q3 		$9.21M Sell
17,857
-18,278
-51% -$9.26M 1.04% 29
2020
Q2 		$16.3M Sell
36,135
-29,521
-45% -$13M 1.86% 9
2020
Q1 		$23M Sell
65,656
-15,185
-19% -$5.58M 3.45% 3
2019
Q4 		$29.9M Buy
80,841
+1,046
+1% +$369K 3.02% 7
2019
Q3 		$26.6M Sell
79,795
-5,053
-6% -$1.65M 2.99% 8
2019
Q2 		$26.5M Buy
84,848
+4,557
+6% +$1.36M 2.85% 9
2019
Q1 		$24.5M Buy
80,291
+33,903
+73% +$9.15M 2.52% 5
2018
Q4 		$10.8M Sell
46,388
-6,002
-11% -$1.61M 1.34% 28
2018
Q3 		$16.4M Sell
52,390
-1,385
-3% -$430K 1.62% 21
2018
Q2 		$15.5M Sell
53,775
-2,435
-4% -$672K 1.58% 20
2018
Q1 		$14.1M Sell
56,210
-12,870
-19% -$3.28M 1.54% 22
2017
Q4 		$16.5M Sell
69,080
-8,527
-11% -$2.07M 1.81% 15
2017
Q3 		$17.2M Sell
77,607
-11,324
-13% -$2.55M 2.06% 8
2017
Q2 		$20.1M Buy
88,931
+9,685
+12% +$2.11M 2.58% 6
2017
Q1 		$15.8M Buy
79,246
+237
+0.3% +$45.6K 2.05% 8
2016
Q4 		$14.4M Sell
79,009
-28,534
-27% -$4.86M 1.94% 6
2016
Q3 		$17.6M Buy
107,543
+21,946
+26% +$3.33M 2.42% 7
2016
Q2 		$12.2M Buy
85,597
+7,489
+10% +$1.07M 1.76% 15
2016
Q1 		$10.7M Buy
78,108
+52,031
+200% +$6.83M 1.43% 19
2015
Q4 		$3.62M Buy
+26,077
New +$3.61M 0.46% 81
2014
Q4 		– Sell
-51,339
Closed -$5.82M – 111
2014
Q3 		$5.82M Buy
51,339
+30,832
+150% +$3.65M 1.32% 22
2014
Q2 		$2.46M Buy
+20,507
New +$2.5M 0.54% 74

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Portolan Capital Management's BIO Position: Q1 2026 in Review

Portolan Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 59% in Q1 2026, selling an estimated $5.76M and leaving 14,173 shares worth $3.95M. The position accounts for 0.21% of the portfolio, ranked #111.

Portolan Capital Management first reported a position in BIO in Q2 2014 and has held it in 44 quarters since. The position peaked at $31.5M in Q1 2024. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Portolan Capital Management held 14,173 shares of Bio-Rad Laboratories Class A worth $3.95M as of Q1 2026.
  • Portolan Capital Management sold 19,986 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $5.76M.
  • Bio-Rad Laboratories Class A made up 0.21% of Portolan Capital Management's portfolio in Q1 2026, its #111 holding.
  • Portolan Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2014 and has held it in 44 quarters since.
  • Portolan Capital Management's Bio-Rad Laboratories Class A position peaked at $31.5M in Q1 2024.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Portolan Capital Management's 13F filing for Q1 2026, filed 15 May 2026.